Mesalamine is expensive primarily because of its complex drug delivery systems, limited generic competition, and the regulatory hurdles that have kept fewer manufacturers in the market. Even with generics now available for several formulations, monthly costs for mesalamine can still run $400 to $900 or more without insurance, making it one of the pricier maintenance medications for ulcerative colitis and other inflammatory bowel conditions.
Complex Delivery Systems Drive Up Manufacturing Costs
Mesalamine isn’t a simple pill. The drug itself is straightforward, but getting it to the right part of your digestive tract without being absorbed too early is an engineering challenge. Different brands use entirely different technologies to solve this problem, and each one adds manufacturing complexity and cost.
Pentasa uses microspheres wrapped in a semipermeable membrane that releases the drug gradually based on time and moisture, distributing it from the upper small intestine all the way to the rectum. Asacol and Delzicol use a pH-sensitive coating designed to dissolve only when it reaches a pH of 7, which prevents the drug from breaking down in the stomach or upper gut. Lialda takes the most elaborate approach: a multi-matrix system where mesalamine is embedded in a fatty matrix, which is itself dispersed within a water-attracting matrix, all wrapped in an enteric coating. When the outer coating dissolves in the terminal ileum, the inner matrices swell into a gel that slowly releases the drug across the entire colon.
These aren’t cosmetic differences. Each system targets a slightly different release pattern, and manufacturing them requires specialized equipment, quality controls, and raw materials that generic tablet production does not. That complexity gets passed along in the price.
Generic Competition Has Been Slow to Arrive
For most drugs, generic versions flood the market once patents expire, and prices drop sharply. With mesalamine, generic entry has been unusually slow. The FDA’s bioequivalence requirements for mesalamine are more demanding than for a typical generic, because the drug works topically on the gut lining rather than systemically in the bloodstream.
For most generics, a manufacturer just needs to show that its version delivers the same amount of drug into the bloodstream at the same rate as the brand name. Mesalamine is different. Because the drug’s effectiveness depends on where in the gut it’s released, regulators argued that standard blood-level comparisons weren’t enough. Earlier guidance even suggested that generic makers would need to run full clinical trials proving their version worked as well as the original, a far more expensive and time-consuming bar to clear.
The FDA eventually shifted to allowing pharmacokinetic studies instead of clinical trials, but with extra requirements. Generic manufacturers must analyze drug absorption over specific time intervals to prove their product releases mesalamine at the same rate and extent in the colon and rectum as the brand name. These additional testing layers mean fewer companies attempt the generic, and those that do spend more time and money getting approval.
Limited Competitors Keep Prices High
Generic competition for mesalamine has picked up in recent years, but the market is still far less crowded than you’d see for something like a generic blood pressure medication. For Apriso, the first generic wasn’t approved until late 2019, with additional manufacturers gaining approval through 2024 and into 2025. That means the generic market for some formulations is only a few years old.
Drug pricing tends to drop meaningfully only when five or more generic manufacturers are actively competing. While Apriso’s generic now has several approved manufacturers (Mylan, Zydus, Aurobindo, and others), not all approved generics are actively produced and distributed at any given time. Some manufacturers hold approvals without shipping product, which limits real-world price competition. For other formulations like Lialda, generic options remain even more limited.
The result is a market where brand-name versions still command high prices, and generics, while cheaper, don’t offer the dramatic discounts patients might expect. A generic mesalamine product might cost 30 to 50 percent less than the brand, rather than the 80 to 90 percent discount common with simpler generics.
It’s a Chronic Medication With No Substitute
Mesalamine is a first-line treatment for mild to moderate ulcerative colitis, and most patients take it indefinitely to maintain remission. There’s no over-the-counter alternative, and the few other drug classes used for IBD (immunosuppressants, biologics) are either more expensive or carry heavier side effects. This gives mesalamine manufacturers pricing leverage: patients and insurers don’t have many places to turn.
The chronic nature of the condition also means you’re not buying a one-time course of antibiotics. You’re filling a prescription every month, potentially for decades, so even modest per-tablet costs compound into significant annual spending.
Ways to Reduce Your Out-of-Pocket Cost
If you’re paying too much for mesalamine, several options can bring costs down substantially.
Switching formulations is one of the simplest strategies. If your doctor has you on a brand-name product, ask whether a generic version of a different mesalamine formulation would work for your condition. For example, generic Apriso or generic Delzicol may be significantly cheaper than brand-name Lialda, even though all contain the same active ingredient.
Patient assistance programs from the manufacturers can provide the drug free or at reduced cost if you qualify. Takeda, which makes Lialda and Pentasa, offers assistance to U.S. residents with household income at or below 500 percent of the federal poverty level who lack prescription coverage. AbbVie runs a similar program for Delzicol and Canasa, primarily for uninsured or underinsured patients, with case-by-case consideration for people on Medicare Part D or other insurance who still can’t afford their copay.
Pharmacy discount programs and manufacturer copay cards can also help. If you have commercial insurance, brand-name copay cards can reduce your share to as little as $10 to $25 per fill. Without insurance, discount platforms sometimes offer generic mesalamine at lower prices than your local pharmacy’s cash rate, so it’s worth comparing across multiple pharmacies and online tools before filling each prescription.